

Awakn Life Sciences to Participate in Upcoming April 2022 Conferences

written by Raj Shah | April 5, 2022

April 5, 2022 ([Source](#)) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Awakn's Chief Executive Officer, is scheduled to present at the following upcoming April 2022 investor conferences.

Sequire Cannabis & Psychedelic Conference

Wednesday, April 20th at 3:00 p.m. ET

To attend, please register [here](#).

KCSA Psychedelics Virtual Investor Conference

Thursday, April 28th at 12:00 p.m. ET

To attend, please register [here](#).

For more information about each conference, or to schedule a one-on-one meeting with Awakn's management team, please contact your appropriate Sequire representative, or alternatively send an emails to KCSA Strategic Communications at Awakn@kcsa.com.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction. Awakn's team consists of renowned research experts and world leading chemists, scientists, psychiatrists, and psychologists. Addiction is one of the biggest unmet medical needs of our time, affecting over 20% of the global population and is an industry valued at over \$100bn per annum. Awakn is

disrupting this underperforming industry by rapidly advancing the next generation of psychedelic drugs and therapies to be used in combination, through preclinical research and clinical stage trials.

www.awaknlifesciences.com | [Twitter](#) | [LinkedIn](#) | [Facebook](#)

Investor Enquiries:

KCSA Strategic Communications

Valter Pinto / Tim Regan

Phone: +1 (212) 896-1254

Awakn@KCSA.com

Media Enquiries:

America and Canada: KCSA Strategic Communications

Anne Donohoe

Adonohoe@KCSA.com

Rest of World: ROAD Communications

Paul Jarman / Nora Popova

Awakn@roadcommunications.co.uk